AlzChem Group (ACT) Q2 2025 earnings summary

Executive summary

• Group sales for H1 2025 reached €287.6 million, slightly above the prior year, with Q2 sales up 4.9% year-over-year, driven mainly by volume growth in Specialty Chemicals.

• Specialty Chemicals was the main growth driver, with H1 sales up 9% to €194.6 million and EBITDA margin rising to 27.7%.

• EBITDA increased by 9% to €56.5 million, and group net income rose 14% to €30.5 million, with EPS at €3.01 per share.

• Free cash flow remained positive despite higher CapEx and inventory buildup, with net cash position at €20 million.

• Major investments in nitroguanidine expansion are on schedule, supported by €51 million in customer grants.

Financial highlights

• H1 2025 sales: €287.6 million (+0.5% year-over-year); Q2 sales up 4.9% year-over-year.

• EBITDA: €56.5 million, up 9% year-over-year; EBITDA margin improved to 19.6% from 18.1%.

• Net income: €30.5 million, up 14% year-over-year; EPS: €3.01.

• Equity ratio decreased to 39.7% as of June 30, 2025, from 42.9% at year-end 2024.

• Free cash flow for H1 2025 at €30.7 million, down 40.2% due to higher investments.

Outlook and guidance

• 2025 sales expected to reach approximately €580 million; EBITDA forecast at least €113 million.

• Growth to be driven by Specialty Chemicals, especially human nutrition, custom manufacturing, and Nitroguanidine volumes.

• No material negative impact expected from U.S. tariffs, but a weaker USD and regulatory risks could affect results.